School PhobiaREPECHNCT07020013
Evaluation of the Effectiveness of Day Hospital Care for Adolescents With Anxious School Refusal
An observational study of School Phobia, run by GCS Ramsay Santé pour l'Enseignement et la Recherche at 1 site in France.
Trial summary
The objective of the study is to evaluate the benefit of day care in a child psychiatric hospital on the return to school and on the development of child psychiatric disorders associated with Anxious Social Refusal. Read more about this study
- Who is it for?
- Ages 12 to 18 years
- Conditions the study is for
- School Phobia
- How many people
- 80 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2025to 30 Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 18 years
- All sexes
- Child, Adult
Study population: Population of patients followed in day hospital for anxious school refusal
Who may be able to join
- Patients aged 12 to 18 years
- Patients with anxious school refusal, defined by a score ≥ 41 on the SCREEN scale
- Patients receiving day hospital care
- Patients who have been informed and whose parents (or holder(s) of parental authority) have agreed to their participation in the study and have not objected to the use of their health data
Who cannot join
- Patients with a mental disability or any other reason that may hinder the understanding or strict application of the protocol
- Patients not affiliated with the French social security system
- Patients under guardianship
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Clinique des 3 cyprès
La Penne-sur-Huveaune, 13821
Solal STORA, MD, 04 28 63 16 01 ext. 33, solal.stora@gmail.com
About this study
The objective of the study is to evaluate the benefit of day care in a child psychiatric hospital on the return to school and on the development of child psychiatric disorders associated with Anxious Social Refusal.
Read the detailed description
This is a prospective, longitudinal, single-center observational cohort study carried out on a population of patients followed in a day hospital for anxious school refusal.
Participating physicians will have the opportunity to recruit their patients over a 12-month period. All enrolled patients will be followed for a minimum of 10 months. The study will be completed as soon as the last enrolled patient has completed a final assessment.
Aside from the baseline visit, each patient will be assessed only once at 10 months. During each patient visit with the investigating physician, the physician will complete an assessment on the electronic CRF.
- Conditions
- School Phobia
- Keywords
- School phobia, Anxious school refusal
- Medical subject headings
- Phobia, School
What is being measured
The primary outcome is the main question the study is designed to answer.
Anxious school refusal
The primary endpoint is based on the change in the SCREEN scale score between inclusion and the end of the study. A 20% improvement in this score will be considered as evidence of a benefit from day hospital care on anxious school refusal.
Measured: Month 10
Secondary outcomes (6)
Obsessive-compulsive disorder assessment
The Yale-Brown Obsession-Compulsion Scale (CY-BOCS) is a structured interview that provides an assessment of the severity of obsessive-compulsive symptoms unbiased by the presence or absence of a particular type of obsession or compulsion.
Measured: Month 10
Anxiety disorder assessment
The Spence Children's Anxiety Scale (SCAS) is a 44-item self-report questionnaire. Each item is rated on a 4-point Likert scale, from 0 (never) to 3 (always). No time period is specified for the scope of the questions.
Six of the 44 items are positive items intended to limit the tendency to respond negatively; they are not included in the overall score.
The overall score, obtained by adding all 38 items, ranges from 0 to 144. The questionnaire identifies six dimensions of anxiety: Panic Attack and Agoraphobia, Separation Anxiety, Fear of Physical Injury, Social Phobia, OCD, and Generalized Anxiety Disorder.
Measured: Month 10
depressive disorder assessment
The Children's Depression Rating Scale - Revised (CDRS) is a revised version of a questionnaire originally derived from the Hamilton Rating Scale for Depression. The total score is an index of the intensity of depressive symptomatology in children aged 6 to 12 years. It is a 17-item, self-assessment tool, completed by a clinician based on a non-directive interview with the child, and supplemented or corrected, based on clinical judgment, with additional information from the family or teachers.
Measured: Month 10
Post traumatic Stress disorder assessment
The UCLA Child/Adolescent Posttraumatic Stress Disorder Reaction Index was designed for use with school-aged children and adolescents. The DSM-5 version is a semi-structured interview with a clinician that assesses a child's trauma history and the full range of DSM-5 symptoms and diagnostic criteria for posttraumatic stress disorder. This measure consists of several parts: an assessment of different types of trauma, a DSM-5 posttraumatic stress disorder symptom scale including dissociative symptoms, and an assessment of distress and impairment.
Measured: Month 10
Attention Deficit Hyperactivity disorder assessment
The ADHD Rating Scale is a specific assessment tool for ADHD. Consisting of the 18 clinical symptoms involved in diagnosing the disorder in the DSM-IV, it quantifies the severity of the disorder and assesses the various dimensions of the disorder (hyperactivity, inattention, and impulsivity). In most clinical studies, a score of 28 or higher is required to qualify ADHD as significant.
Measured: Month 10
Schooling method
Current schooling method (or planned in the short term) at month 10
Measured: Month 10
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2025
- Study start1 Sep 2025 (estimated)
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for School PhobiaStudies of the same condition, open and under way.
- More trials run by GCS Ramsay Santé pour l'Enseignement et la RechercheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07020013
- Sponsor's protocol ID
- 2025-A00523-46
- Acronym
- REPECH
- Status last verified
- Jun 2025
- First submitted
- 5 Jun 2025
- Last updated
- 13 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effectiveness of Day Hospital Care for Adolescents With Anxious School Refusal
- ClinicalTrials.gov ID
- NCT07020013
- Acronym / sponsor ID
- REPECH / 2025-A00523-46
- Conditions
- School Phobia
- Keywords
- School phobia, Anxious school refusal
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- GCS Ramsay Santé pour l'Enseignement et la RechercheUniversity, hospital or other
- Study start
- 1 Sep 2025 (estimated)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 13 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to evaluate the benefit of day care in a child psychiatric hospital on the return to school and on the development of child psychiatric disorders associated with Anxious Social Refusal.
Detailed description
This is a prospective, longitudinal, single-center observational cohort study carried out on a population of patients followed in a day hospital for anxious school refusal.
Participating physicians will have the opportunity to recruit their patients over a 12-month period. All enrolled patients will be followed for a minimum of 10 months. The study will be completed as soon as the last enrolled patient has completed a final assessment.
Aside from the baseline visit, each patient will be assessed only once at 10 months. During each patient visit with the investigating physician, the physician will complete an assessment on the electronic CRF.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 12 to 18 years
- Sex
- All
- Age groups
- Child, Adult
- Study population
- Population of patients followed in day hospital for anxious school refusal
Key inclusion criteria (4 listed)
- Patients aged 12 to 18 years
- Patients with anxious school refusal, defined by a score ≥ 41 on the SCREEN scale
- Patients receiving day hospital care
- Patients who have been informed and whose parents (or holder(s) of parental authority) have agreed to their participation in the study and have not objected to the use of their health data
Key exclusion criteria (3 listed)
- Patients with a mental disability or any other reason that may hinder the understanding or strict application of the protocol
- Patients not affiliated with the French social security system
- Patients under guardianship
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Anxious school refusal
Time frame: Month 10
The primary endpoint is based on the change in the SCREEN scale score between inclusion and the end of the study. A 20% improvement in this score will be considered as evidence of a benefit from day hospital care on anxious school refusal.
6 secondary outcomes
Obsessive-compulsive disorder assessment
Time frame: Month 10
Anxiety disorder assessment
Time frame: Month 10
depressive disorder assessment
Time frame: Month 10
Post traumatic Stress disorder assessment
Time frame: Month 10
Attention Deficit Hyperactivity disorder assessment
Time frame: Month 10
Schooling method
Time frame: Month 10
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for School Phobia
Recruiting
School-based Treatment of Social Anxiety With Developmentally Oriented Cognitive Therapy for Social Anxiety Disorder
Social Anxiety Disorder, Social Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of School Phobia, run by GCS Ramsay Santé pour l'Enseignement et la Recherche at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact solal STORA, MD (04 28 63 16 01 ext. 33, solal.stora@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anxious school refusal (time frame: Month 10). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jun 2025.